NCT01088464View on ClinicalTrials.gov

Study of IMC-11F8 in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Neoplasms
Interventions
BIOLOGICAL

IMC-11F8

600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks

BIOLOGICAL

IMC-11F8

800 mg intravenously, every 2 weeks

BIOLOGICAL

IMC-11F8

800 mg intravenously, Days 1 and 8 every 3 weeks

Trial Locations (1)

104-0045

ImClone Investigational Site, Tokyo

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY